But combined with a GLP-1 receptor agonist it amplifies appetite suppression and adds distinct benefits through fat tissue and brain reward pathways that GLP-1 alone does not fully address
GLP-1 enhances glucose metabolism by stimulating insulin secretion when blood sugar levels rise, inhibiting glucagon release, and slowing gastric emptying to regulate nutrient absorption
However, clinical trials of emphysema patients with and without AATD have failed to demonstrate measurable improvements in lung destruction
Nu nm do ni tit, thuc, bnh l hoc vim da, ngi dng nn khm chuyn khoa c nh gi nguyn nhn
, 1 2
still, for most people semaglutide should be good enough 1 Like Neo September 8, 2024, 8:26pm #5 RapAdmin: tested in the ITP program They should something in this broader family, but issues in the past has been needs to be pill/food based and not subcutaneous injections 1 Like Neo September 8, 2024, 8:27pm #6 AlexKChen: widely available on various peptide sites now Any sense of this increased baseline insulin levels, thats my worry with GLP-1 as CR mimetic that key longevity pathway (and IGF, etc) might actually go in the wrong direction with these HealthspanMaximalist September 10, 2024, 2:07am #7 2.2% is quite a large A1C reduction (although the sample size was not that big)
